SUMMARY Ninety-nine adult mongrel dogs underwent acute ligation of the proximal left anterior descending coronary artery. Thirty minutes later, the occlusion was released to evaluate the effectiveness of five antiarrhythmic protocols in eliminating reperfusion ventricular fibrillation. The five protocols included: protocol 1 -i.v. lidocaine, preligation and prerelease (n = 19); protocol 2 i.v. lidocaine, prereperfusion only (n = 22); protocol 3 chronic, oral, daily amiodarone for 2 weeks preligation (n = 19); protocol 4 -i.v. procainamide, preligation and prereperfusion (n = 21); and protocol 5 i.v. verapamil, prereperfusion (n = 18). Each regimen was evaluated with respect to the incidence of reperfusion ventricular fibrillation in dogs that survived to reperfusion, and the results were compared to 77 control dogs that underwent identical coronary artery occlusion and release procedures without drug therapy. The incidence of reperfusion ventricular fibrillation was as follows: protocol I -seven of 15 dogs (47%); protocol 2 -six of 18 (33%); protocol 3 11 of 16 dogs (69%); protocol 4-eight of 17 dogs (47%); and protocol 5-10 of 17 dogs (59%), compared with 36 of 60 (60%) in control dogs.
arrhythmic drug interventions has led to equivocal and contradictory results. [17] [18] [19] [20] Other studies, using either coronary artery ligation or reperfusion models, have also suggested that a large and variable number of animals do not develop ventricular fibrillation, even without prior antiarrhythmic therapy (approximately 60% and 30%, respectively).2 29 Previous studies in this laboratory, however, indicate that the risk for developing ventricular fibrillation on reperfusion might be predicted for individual animals based on the incidence, time course and severity of arrhythmias occurring during the antecedent period of acute coronary artery ligation. 30' 31 This was predicated on the observation that different animals subjected to acute one-stage ligation of the proximal left anterior descending coronary artery developed either immediate (occurring 2-12 minutes after ligation), delayed (occurring 14-30 minutes after ligation), both types or no ventricular arrhythmias at all;32' 33 and that the risk for ventricular fibrillation during the subsequent period of coronary artery reperfusion correlated closely with the occurrence of these ligation arrhythmias. 30 31 In the present study we evaluated the effectiveness of lidocaine, procainamide, amiodarone and verapamil in preventing ventricular fibrillation after acute coronary artery reperfusion. For this purpose, the results of various treatment protocols were compared, adjusting for differences in the arrhythmic events that occurred during earlier periods of coronary artery ligation. Using these methods, we have avoided some of the limitations imposed by the inconsistencies reported in previous studies.
Methods Ninety-nine dogs were studied on various drug regimens. Adult 15-30-kg mongrel dogs were anesthetized with i.v. pentobarbital sodium, 30 mg/kg, and immediately intubated. Room air ventilation was maintained with a Harvard respirator and body temperature was maintained with a thermal blanket. A #8F NIH catheter was introduced into the ascending aorta via the femoral artery to monitor the aortic pressure throughout each experiment. The chest was opened through the fifth left intercostal space, the pericardium opened and the heart suspended in a pericardial cradle. The left anterior descending coronary artery was dissected free and a snare was positioned within 2 cm of its origin and proximal to all diagonal branches. Two surface ECG leads were monitored continuously on a C-59 Tektronix storage oscilloscope and recorded on a Model #4578A Hewlett-Packard eight-channel photographic recorder. In all dogs the coronary artery was ligated in one stage, the occlusion maintained for 30 minutes and then acutely released. At the time of release, the vessel was gently kneaded to ensure rapid return of maximum pulsatile blood flow. A 30-minute period of coronary artery ligation was chosen to incorporate both the immediate and delayed ligation ventricular arrhythmias and because previous studies showed that the incidence of ventricular fibrillation after reperfusion was highest after a li gation period of this duration. 30 Whenever ventricular fibrillation occurred, dogs received DC shocks of 10 watt-sec and if fibrillation persisted, a second shock of 40 watt-sec was delivered to the heart. Dogs that were successfully resuscitated after no more than the two attempts described were considered appropriate for reperfusion.
The dogs were divided into five subgroups. Drug regimens were chosen to facilitate both optimal plasma and tissue levels in both normal and ischemic myocardium at the time of reperfusion, 30 Twenty-two dogs that underwent coronary artery ligation were included in this group, but only 18 survived to the reperfusion phase. A bolus of 1.0 mg/kg of lidocaine was given 3 minutes before the release of the occlusion, followed by a 0.07-mg/kg/min i.v. infusion to the 18 dogs that survived coronary artery ligation. This protocol was included so we could exclude any effects of lidocaine on the occurrence of reperfusion ventricular arrhythmias caused by the effects of lidocaine during the period of coronary artery ligation (drug protocol 1).
Drug Protocol 3, Amiodarone
Nineteen dogs received 10 mg/kg of amiodarone orally every day for 14 days before acute occlusion of the left anterior descending coronary artery.
Drug Protocol 4, Procainamide
Twenty-one dogs received an i.v. bolus of 20 mg/kg of procainamide 30 minutes before coronary artery ligation, over 2 minutes, followed by a 0. 1-mg/kg/min infusion that was continued throughout ligation and reperfusion. Twenty minutes after ligation and 10 minutes before reperfusion, the 17 surviving dogs received a second bolus of 10 mg/kg of procainamide.
Drug Protocol 5, Verapamil Eighteen dogs were included in the verapamil protocol and 17 survived to reperfusion. Seven minutes before reperfusion, each of these animals received 0.2 mg/kg of i.v. verapamil. Because previously published drug protocols were adhered to, blood levels were not monitored on the various treatment protocols.
Control Dogs
Seventy-seven control dogs were treated identically except that no antiarrhythmic agents were administered either before coronary artery ligation, during ligation or during coronary artery reperfusion. Nineteen dogs were pretreated with lidocaine, as detailed in the Methods ( fig. 2) . Three (16%) had no ventricular arrhythmias during coronary artery ligation, four (21%) died of refractory ventricular fibrillation during the period of IVA, and eight of 19 dogs (42%) developed ventricular fibrillation during coronary ligation. None of these results differed from the control group (i.e., treatment with lodicaine preligation in this manner did not affect the appearance of these ligation ventricular arrhythmias). Twelve dogs with ligation ventricular arrhythmias survived to reperfusion, including four dogs with ligation-related fig. 3) . Dogs treated in this manner were comparable to the controls and to the dogs treated with lidocaine before both ligation and reperfusion (i.e., drug protocol 1) with respect to the number (i.e., proportion) of dogs free of ventricular arrhythmias during the coronary artery ligation period, the number of dogs that died with ventricular fibrillation during the period of IVA, and in the number with ventricular fibrillation during the period of ligation (p > 0.10). Eleven dogs with ventricular arrhythmias during ligation survived to reperfusion, including three dogs with ligation ventricular fibrillation. We predicted that 9.0 (82%) of these 1 1 dogs would have incurred ventricular fibrillation with reperfusion, but only six (54.5%) did. However, this difference was not statistically significant (p > 0.10).
Drug Protocol 3 Nineteen dogs were pretreated with amiodarone before coronary artery ligation, as described in the Methods (fig. 4) . Compared with controls, there was no difference during the coronary artery ligation period in the number of dogs that died with refractory ventricular fibrillation during IVA or in the number of dogs with ventricular fibrillation during coronary artery ligation (p > 0.10). Thus, 13 dogs were subjected to coronary artery reperfusion, including five dogs resuscitated from ventricular fibrillation; these dogs were no different from the controls with respect to the incidence of arrhythmias during ligation. We predicted that 10.5 of these 13 dogs (81 %) would have succumbed to reperfusion ventricular fibrillation, and 11 (85%) Eighteen dogs underwent coronary artery ligation and subsequent i.v. verapamil treatment before reperfusion, as detailed in the Methods. Their course is detailed in figure 6 . We predicted that 8.9 of the 11 dogs (81 %) with ligation ventricular arrhythmias surviving to reperfusion would have had ventricular fibrillation with reperfusion, and 10 (91%) did so. This difference was not statistically significant (p > 0.10).
Summary Data
Fifty-eight of the dogs (58%) in the different drugtreated groups survived to reperfusion. Using the predictive indexes derived from the control dogs, we expected that 47.7 of these 58 dogs (82%) surviving to reperfusion in the drug-treated groups would have incurred reperfusion ventricular fibrillation, and 42 (72%) did. This difference was not statistically significant (p > 0.10). Nineteen dogs in the drug-treated groups were resuscitated from ventricular fibrillation during coronary artery ligation and were subsequently reperfused; 18 of these 19 dogs (95%) again suffered ventricular fibrillation on reperfusion, vs 17 of 17 (100%) (NS) for the control dogs. None of the 16 control dogs free of ventricular arrhythmias during coronary artery ligation suffered ventricular fibrillation during reperfusion. Similarly, none of the 25 dogs in the drug-treated groups free of ventricular arrhythmias during antecedent ligation suffered ventricular fibrillation during reperfusion. Dogs free of reperfusion arrhythmias were not distinguishable on the basis of the prereperfusion heart rates or blood pressures. All control and drug-treated dogs resuscitated from ventricular fibrillation occurring during the ligation period of IVA also had ventricular arrhythmias during the delayed ligation period ( figs. 1-6 ). Thus, no control or drug-treated dogs resuscitated from ventricular fibrillation during the immediate ligation period, but free of delayed ligation arrhythmias, were available for reperfusion or further analysis.
Also important to this analysis was the demonstration that dogs treated before ligation (protocols 1, 3 and 4) were apparently no different from dogs not pretreated, with respect to their distribution into subgroups at different risks for reperfusion ventricular fibrillation. Small differences were consistent with spontaneous variability. In addition, because multiple comparisons were being tested (i.e., five protocols vs controls) in this study, consideration of the Bonferroni adjustment is appropriate. Thus, an approximately 0.05/5 = 0.01 level of significance would be required to demonstrate, conservatively, a reduction in the incidence of reperfusion ventricular fibrillation attributable to a drug protocol. Discussion The purpose of the present study was to evaluate the effectiveness of a spectrum of antiarrhythmic agents with diverse electrophysiologic properties in preventing reperfusion-related ventricular fibrillation. In this malignant model, we have focused on the lethal end point of ventricular fibrillation, rather than electrophysiologic markers such as ventricular ectopy or fractionation of local electrograms. [10] [11] [12] The design of this study allowed us to evaluate these agents with respect to their roles in both the primary (prophylactic, before an ischemic event) and secondary (postischemic, before reperfusion) prevention of ventricular fibrillation.
Primary Antiarrhythmic Prophylaxis
Initiation of antiarrhythmic therapy with either lidocaine, amiodarone, or procainamide before ligation did not eliminate, and did not even reduce significantly (p > 0.10) the occurrence of ventricular fibrillation resulting from reperfusion 30 minutes after acute coronary artery ligation. Furthermore, these same agents were also ineffective in reducing the incidence of ventricular fibrillation and ventricular arrhythmias during the antecedent 30-minute periods of coronary artery ligation. Initiation of antiarrhythmic therapy before initial ligation in this study was done in accord with previously reported pharmacokinetic data to ensure that adequate drug concentrations were not only circulating, but were also present in both normal and presumably ischemic myocardium. 34, 41 These findings have two implications. First, chronic and prophylactic primary (i.e., before any ischemic event) administration of lidoacine, amiodarone or procainamide would not be expected to be optimally protective against subsequent reperfusion-related ventricular fibrillation.
Second, chronic administration of amiodarone would not be adequate prophylaxis against ventricular fibrillation occurring as a result of either acute coronary artery ligation or subsequent reperfusion. In addition, the present data suggest that lidocaine and procainamide are also not protective against ligation ventricular arrhythmias. However, these results do not preclude the possibility that additional benefit might have been derived from the administration of lidocaine or procainamide either in higher doses or for longer durations before coronary artery ligation.
Secondary Antiarrhythmic Prophylaxis
Secondary prophylaxis refers to administration of antiarrhythmic therapy after the onset of an acute ischemic event. In the present study, neither lidocaine nor verapamil was dramatically or significantly (p > 0.10) successful in preventing reperfusion ventricular fibrillation when administered after occlusion but before reperfusion. The continuation or supplementation after occlusion of lidocaine, procainamide, or amiodarone treatment that had been initiated before occlusion was also inadequate to protect optimally against reperfusion ventricular fibrillation.
The methods of the present study have also taken into account the spontaneous variability that individual animals demonstrate in their susceptibility to both ligation and reperfusion arrhythmias, whether or not they receive antiarrhythmic therapy. First, by using one large control group, rather than a parallel design with multiple smaller control groups, we could identify subgroups among the controls at widely varying risks for reperfusion ventricular fibrillation. We then calculated the risks for these subgroups based on the arrhythmic events of the antecedent periods of coronary artery ligation. Second, by applying an appropriate statistical method, we could take into account spontaneous differences in the proportions of dogs that fell into these different subgroups. 
